Corcept Therapeutics (CORT) Long-Term Investments (2017 - 2026)

Corcept Therapeutics has disclosed Long-Term Investments across 10 years of filings, most recently posting $177.3 million for Q1 2026.

• Long-Term Investments for Q1 2026 came in at $177.3 million, down 28.54% year-over-year; the trailing twelve-month figure through Mar 2026 was $177.3 million (down 28.54% YoY), and the FY2025 annual result was $160.3 million, down 27.09% from the prior year.
• Long-Term Investments came in at $177.3 million for Q1 2026 at Corcept Therapeutics, up from $160.3 million in the prior quarter.
• In the past five years, Long-Term Investments ranged from a high of $248.0 million in Q1 2025 to a low of $4.9 million in Q3 2022.
• The 5-year median for Long-Term Investments is $59.6 million (2023), against an average of $97.9 million.
• Across the five-year window, Long-Term Investments slumped 96.34% in 2022 and surged 1118.0% in 2023, its largest moves.
• Corcept Therapeutics' Long-Term Investments stood at $4.9 million in 2022, then soared by 1055.77% to $57.2 million in 2023, then surged by 284.48% to $219.8 million in 2024, then slipped by 27.09% to $160.3 million in 2025, then climbed by 10.6% to $177.3 million in 2026.
• The last three Long-Term Investments figures came in at $177.3 million (Q1 2026), $160.3 million (Q4 2025), and $102.6 million (Q3 2025), per Business Quant data.